Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Little information has been published on the use of tyrosine kinase inhibitors for treatment of patients undergoing hemodialysis (HD). We investigated the efficacy and safety of sorafenib for metastatic renal cell carcinoma (mRCC) patients undergoing HD.

Methods

Twenty patients undergoing HD were treated with sorafenib as first-line therapy for mRCC at our hospital between April 2008 and August 2014. Patient medical records were retrospectively reviewed to evaluate the response to sorafenib and treatment-related toxicity.

Results

Fifteen and 5 patients were classified in the intermediate and poor risk groups, respectively, of the Memorial Sloan–Kettering Cancer Center risk model. Eighteen patients had 3 or more metastatic lesions, and 7 patients had metastases in 2 or more organs. Of 16 patients who had previously undergone nephrectomy, 8 were pathologically diagnosed with non-clear-cell carcinoma. The median duration of sorafenib therapy was 4.7 months. Sorafenib was discontinued owing to progressing disease for 15 patients and because of serious adverse events (AE) (≥grade 3) for 4 patients, i.e. subarachnoid hemorrhage, cerebral hemorrhage, sepsis, and syncope for 1 patient each. Median time to progression was 6.3 months, and median overall survival was 14.2 months.

Conclusions

In this study, many patients had unfavorable clinical features, for example poor risk classification and metastases in multiple organs. Although sorafenib treatment of HD patients seems feasible, careful monitoring is needed because of the tendency for a high incidence of serious AE, even when a reduced dose is administered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ishikawa I, Saito Y, Shikura N et al (1990) Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 16:452–458

    Article  CAS  PubMed  Google Scholar 

  2. Terasawa Y, Suzuki Y, Morita M et al (1994) Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients. J Urol 152:846–851

    CAS  PubMed  Google Scholar 

  3. Denton MD, Magee CC, Ovuworie C et al (2002) Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 61:2201–2209

    Article  PubMed  Google Scholar 

  4. Schwarz A, Vatandaslar S, Merkel S et al (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2:750–756

    Article  PubMed  Google Scholar 

  5. Neuzillet Y, Tillou X, Mathieu R et al (2011) Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 60:366–373

    Article  PubMed  Google Scholar 

  6. Nouh MA, Kuroda N, Yamashita M et al (2010) Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 105:620–627

    Article  PubMed  Google Scholar 

  7. Syrios J, Kechagias G, Tsavaris N (2013) Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol 14:84

    Article  PubMed Central  PubMed  Google Scholar 

  8. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  CAS  PubMed  Google Scholar 

  9. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  CAS  PubMed  Google Scholar 

  10. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972

    Article  CAS  PubMed  Google Scholar 

  11. Clark JW, Eder JP, Ryan D et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472–5480

    Article  CAS  PubMed  Google Scholar 

  12. Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688–1694

    Article  CAS  PubMed  Google Scholar 

  13. Ruppin S, Protzel C, Klebingat KJ et al (2009) Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol 55:986–988 (quiz 988)

    Article  PubMed  Google Scholar 

  14. Shinsako K, Mizuno T, Terada T et al (2010) Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 15:512–514

    Article  PubMed  Google Scholar 

  15. Rey PM, Villavicencio H (2008) Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 74:245–246

    Article  PubMed  Google Scholar 

  16. Masini C, Sabbatini R, Porta C et al (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 110:692–698

    Article  CAS  PubMed  Google Scholar 

  17. Kennoki T, Kondo T, Kimata N et al (2011) Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 41:647–655

    Article  PubMed  Google Scholar 

  18. Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145–1153

    Article  CAS  PubMed  Google Scholar 

  19. Heng DY, Choueiri TK, Rini BI et al (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149–154

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280–1289

    Article  CAS  PubMed  Google Scholar 

  22. Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762

    Article  PubMed  Google Scholar 

  23. Uemura H, Shinohara N, Yuasa T et al (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194–202

    Article  PubMed  Google Scholar 

  24. Procopio G, Bellmunt J, Dutcher J et al (2013) Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 108:311–318

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Hutson TE, Bellmunt J, Porta C et al (2010) Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46:2432–2440

    Article  CAS  PubMed  Google Scholar 

  26. Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116:1272–1280

    Article  CAS  PubMed  Google Scholar 

  27. Hutson TE, Lesovoy V, Al-Shukri S et al (2013) Axitinib vs. sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14:1287–1294

    Article  CAS  PubMed  Google Scholar 

  28. Motzer RJ, Nosov D, Eisen T et al (2013) Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31:3791–3799

    Article  CAS  PubMed  Google Scholar 

  29. Harnett JD, Foley RN, Kent GM et al (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884–890

    Article  CAS  PubMed  Google Scholar 

  30. Agarwal R (2005) Hypertension and survival in chronic hemodialysis patients–past lessons and future opportunities. Kidney Int 67:1–13

    Article  PubMed  Google Scholar 

  31. Longenecker JC, Coresh J, Powe NR et al (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13:1918–1927

    Article  PubMed  Google Scholar 

  32. Yasuda Y, Saito K, Yuasa T et al (2013) Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18(5):884–889

    Article  CAS  PubMed  Google Scholar 

  33. Omae K, Kondo T, Tanabe K (2014) High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. Urol Oncol 33(2):67.e9–67.e13

  34. Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607–610

    Article  CAS  PubMed  Google Scholar 

  35. Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 35:97–105

    Article  CAS  PubMed  Google Scholar 

  36. Trédan O, Galmarini CM, Patel K et al (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454

    Article  PubMed  Google Scholar 

  37. Mancino A, Lawrence T (2010) Nuclear factor-kappaB and tumor-associated macrophages. Clin Cancer Res 16:784–789

    Article  CAS  PubMed  Google Scholar 

  38. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322

    Article  CAS  PubMed  Google Scholar 

  39. Filiopoulos V, Vlassopoulos D (2009) Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 8:369–382

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Noriko Hata for secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Urology, Tokyo Women’s Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Kenji Omae, Tsunenori Kondo, Takafumi Kennoki, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Yasunobu Hashimoto & Kazunari Tanabe

Authors
  1. Kenji Omae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsunenori Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takafumi Kennoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshio Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junpei Iizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirohito Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasunobu Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazunari Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Omae.

Ethics declarations

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omae, K., Kondo, T., Kennoki, T. et al. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int J Clin Oncol 21, 126–132 (2016). https://doi.org/10.1007/s10147-015-0871-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0871-y

Keywords

Search

Navigation